XNAS
CURX
Market cap6mUSD
Oct 08, Last price
4.76USD
1D
-0.21%
1Q
6.82%
IPO
-94.89%
Name
Curanex Pharmaceuticals Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
Key people
Liqin Xie
Chief Operating Officer · since 2024
Ning Zhang
Chief Technology Officer · since 2024
Wanjun Zhang
Chief Financial Officer, Treasurer · since 2026
Huijuan Zhong
Chief Science Officer · since 2024
Dian Ying Jing
Secretary, Director
Jun Liu
President, Chief Executive Officer, Director · since 2024
Yanming Du
Independent Director · since 2024
Xiaohui Hao
Independent Director · since 2024
Yong Yan
Independent Director · since 2024
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | |
| Income | ||||
Revenues | ||||
Cost of revenue | ||||
Unusual Expense (Income) | ||||
NOPBT | ||||
NOPBT Margin | ||||
Operating Taxes | ||||
Tax Rate | ||||
NOPAT | ||||
Net income | ||||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | ||||
BB yield | ||||
| Debt | ||||
Debt current | ||||
Long-term debt | ||||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | ||||
| Cash flow | ||||
Cash from operating activities | ||||
CAPEX | ||||
Cash from investing activities | ||||
Cash from financing activities | ||||
FCF | ||||
| Balance | ||||
Cash | ||||
Long term investments | ||||
Excess cash | ||||
Stockholders' equity | ||||
Invested Capital | ||||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | ||||
Price | ||||
Market cap | ||||
EV | ||||
EBITDA | ||||
EV/EBITDA | ||||
Interest | ||||
Interest/NOPBT |